ondansetron has been researched along with Substance Withdrawal Syndrome in 39 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Substance Withdrawal Syndrome: Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, we investigated the co-administration of ondansetron with morphine, and whether it could prevent the development of physical dependence in patients taking opioids for the treatment of chronic pain." | 5.27 | Ondansetron does not prevent physical dependence in patients taking opioid medications chronically for pain control. ( Carroll, I; Chu, LF; Clark, JD; Clemenson, A; Cornell, E; Crawford, CW; Encisco, EM; Erlendson, MJ; Gamble, JG; Obasi, H; Okada, R; Rico, T; Sun, J; Vertelney, H, 2018) |
| "The vital signs, withdrawal symptoms and the frequency requirement of fentanyl were recorded during anesthesia, and opioid (pethidine) analgesic was received during the recovery period." | 2.90 | Impact of Ondansetron on Withdrawal Signs, Fentanyl Requirement and Pain Relief in Opioid-addicted Patients under General Anesthesia. ( Dehesh, T; Hashemian, M; Jafari, E; Jafari, M; Mahikhan, F; Rahimi, HR, 2019) |
| "Ondansetron pretreatment did not have a significant effect on the imaging correlates of opioid withdrawal." | 2.80 | Acute opioid withdrawal is associated with increased neural activity in reward-processing centers in healthy men: A functional magnetic resonance imaging study. ( Alva, H; Chu, LF; Clark, JD; Clemenson, A; Encisco, E; Erlendson, M; Hoang, D; Lin, JC; Sun, J; Younger, JW, 2015) |
| "Ondansetron was well tolerated and no serious adverse events were registered." | 2.78 | A pilot study of full-dose ondansetron to treat heavy-drinking men withdrawing from alcohol in Brazil. ( Baltieri, DA; Corrêa Filho, JM, 2013) |
| " The percentage of reduction of benzodiazepine daily dosage at all time points in the treatment trial was similar for the ondansetron and placebo groups." | 2.69 | A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation. ( Busto, UE; Kaplan, HL; Romach, MK; Sellers, EM; Somer, G, 1998) |
| "The ondansetron treated rats showed only a non-significant decrease in break point." | 1.31 | Ondansetron given in the acute withdrawal from a repeated cocaine sensitization dosing regimen reverses the expression of sensitization and inhibits self-administration. ( Davidson, C; Ellinwood, EH; Lee, TH; Xiong, Z, 2002) |
| " In contrast, daily injections of ondansetron with cocaine significantly blocked the development of sensitization with an inverted U-shape dose-response curve." | 1.30 | Blockade of cocaine sensitization and tolerance by the co-administration of ondansetron, a 5-HT3 receptor antagonist, and cocaine. ( Ellinwood, EH; King, GR; Xiong, Z, 1997) |
| "Withdrawal symptoms were still present 24 h after detoxification and 80% of the patients relapsed during a 6-month follow-up." | 1.30 | Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term results. ( Bertschy, G; Cucchia, AT; Ferrero, F; Monnat, M; Spagnoli, J, 1998) |
| "Ondansetron was without effect on working memory errors, but significantly increased the number of reference memory errors made by the ex-ethanol group." | 1.29 | The role of 5-HT in the anxiogenic effects of acute ethanol withdrawal and in the long-lasting cognitive deficits. ( al-Farhan, M; Andrews, N; File, SE; Wu, PY, 1993) |
| " Three tests were used in which the benzodiazepine antagonist flumazenil was administered to rats receiving chronic administration of chlordiazepoxide." | 1.29 | Conflicting evidence regarding the efficacy of ondansetron in benzodiazepine withdrawal. ( Emmett-Oglesby, MW; Hooper, ML; Lal, H; Lane, JD; Lytle, DA; Prather, PL; Rezazadeh, SM; Rowan, GA, 1993) |
| " Chronic administration of morphine (10 mg/kg i." | 1.29 | Prevention of morphine discontinuation phenomenon in mice by ondansetron, a selective 5-HT3 antagonist. ( Kulkarni, SK; Roychoudhury, M, 1996) |
| "01 mg/kg IP, twice daily for 14 days) produced a significant anxiolytic profile which was not a result of handling during the chronic dosing schedule, an effect was not measureable 24 h after treatment ended." | 1.28 | Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze. ( Heaton, M; Marsden, CA; Upton, N; Wright, IK, 1992) |
| "Pre-treatment with ondansetron (0." | 1.28 | Effects of 5-HT3 receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal. ( Higgins, GA; Joharchi, N; Nguyen, P; Sellers, EM, 1991) |
| " These data support recent claims that GR38032F attenuates benzodiazepine withdrawal, and they indicate that this effect shows an inverted U-shaped dose-response curve." | 1.28 | Effects of the 5-HT3 antagonist GR38032F (ondansetron) on benzodiazepine withdrawal in rats. ( Goudie, AJ; Leathley, MJ, 1990) |
| "Buspirone was ineffective." | 1.28 | The effects of ondansetron (GR38032F) in rats and mice treated subchronically with diazepam. ( Costall, B; Jones, BJ; Kelly, ME; Naylor, RJ; Oakley, NR; Onaivi, ES; Tyers, MB, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.56) | 18.7374 |
| 1990's | 24 (61.54) | 18.2507 |
| 2000's | 5 (12.82) | 29.6817 |
| 2010's | 9 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, LF | 2 |
| Rico, T | 1 |
| Cornell, E | 1 |
| Obasi, H | 1 |
| Encisco, EM | 1 |
| Vertelney, H | 1 |
| Gamble, JG | 1 |
| Crawford, CW | 1 |
| Sun, J | 2 |
| Clemenson, A | 2 |
| Erlendson, MJ | 1 |
| Okada, R | 1 |
| Carroll, I | 1 |
| Clark, JD | 2 |
| Peltz, G | 1 |
| Südhof, TC | 1 |
| Mahikhan, F | 1 |
| Hashemian, M | 1 |
| Dehesh, T | 1 |
| Jafari, E | 1 |
| Jafari, M | 1 |
| Rahimi, HR | 1 |
| Ward, HB | 1 |
| Barnett, BS | 1 |
| Suzuki, J | 1 |
| Lin, JC | 1 |
| Encisco, E | 1 |
| Hoang, D | 1 |
| Alva, H | 1 |
| Erlendson, M | 1 |
| Younger, JW | 1 |
| Brantley, E | 1 |
| Cohn, J | 1 |
| Babu, K | 1 |
| Vadivelu, S | 1 |
| Tomlinson, K | 1 |
| Valles, J | 1 |
| Hundert, M | 1 |
| Bagdonas, R | 1 |
| Eisenberg, M | 1 |
| Heinl, C | 1 |
| Drdla-Schutting, R | 1 |
| Xanthos, DN | 1 |
| Sandkühler, J | 1 |
| de Oliveira Citó, Mdo C | 1 |
| da Silva, FC | 1 |
| Silva, MI | 1 |
| Moura, BA | 1 |
| Macêdo, DS | 1 |
| Woods, DJ | 1 |
| Fonteles, MM | 1 |
| de Vasconcelos, SM | 1 |
| de Sousa, FC | 1 |
| Corrêa Filho, JM | 1 |
| Baltieri, DA | 1 |
| Davidson, C | 3 |
| Lee, TH | 3 |
| Xiong, Z | 3 |
| Ellinwood, EH | 6 |
| Lazarus, C | 1 |
| Gopalan, R | 1 |
| Ahn, C | 1 |
| Chen, Q | 1 |
| Mannelli, P | 1 |
| Patkar, AA | 1 |
| Weese, GD | 1 |
| Kwon, P | 1 |
| Lefkowitz, W | 1 |
| File, SE | 1 |
| Andrews, N | 1 |
| al-Farhan, M | 1 |
| Wu, PY | 1 |
| Sell, LA | 1 |
| Cowen, PJ | 1 |
| Robson, PJ | 1 |
| Prather, PL | 2 |
| Rezazadeh, SM | 2 |
| Lane, JD | 1 |
| Rowan, GA | 1 |
| Hooper, ML | 1 |
| Lytle, DA | 1 |
| Emmett-Oglesby, MW | 2 |
| Lal, H | 2 |
| Mizoguchi, H | 1 |
| Shirayama, N | 1 |
| Tsuda, M | 1 |
| Yoshiike, M | 1 |
| Suzuki, T | 2 |
| Misawa, M | 2 |
| King, GR | 3 |
| Joyner, CM | 1 |
| Borg, PJ | 1 |
| Taylor, DA | 1 |
| Loimer, N | 1 |
| Hofmann, P | 1 |
| Chaudhry, H | 1 |
| Bhattacharya, SK | 1 |
| Chakrabarti, A | 1 |
| Sandler, M | 1 |
| Glover, V | 1 |
| West, R | 1 |
| Hajek, P | 1 |
| Roychoudhury, M | 1 |
| Kulkarni, SK | 1 |
| Ise, Y | 1 |
| Mori, T | 1 |
| Pinelli, A | 1 |
| Trivulzio, S | 1 |
| Tomasoni, L | 1 |
| Romach, MK | 1 |
| Kaplan, HL | 1 |
| Busto, UE | 1 |
| Somer, G | 1 |
| Sellers, EM | 2 |
| Cucchia, AT | 1 |
| Monnat, M | 1 |
| Spagnoli, J | 1 |
| Ferrero, F | 1 |
| Bertschy, G | 1 |
| Raby, WN | 1 |
| Wright, IK | 1 |
| Heaton, M | 1 |
| Upton, N | 1 |
| Marsden, CA | 1 |
| Goudie, AJ | 2 |
| Leathley, MJ | 2 |
| Higgins, GA | 1 |
| Nguyen, P | 1 |
| Joharchi, N | 1 |
| Costall, B | 3 |
| Jones, BJ | 3 |
| Kelly, ME | 3 |
| Naylor, RJ | 3 |
| Onaivi, ES | 3 |
| Tyers, MB | 3 |
| Oakley, NR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence[NCT01549652] | 133 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| fMRI Imaging of Opioid Withdrawal in Healthy Human Volunteers[NCT01006707] | 15 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
| Examination of Palonosetron and Hydroxyzine Pre-treatment as a Possible Method to Reduce the Objective Signs of Experimentally-induced Acute Opioid Withdrawal in Humans: a Double-blind, Randomized, Placebo-controlled Crossover Study[NCT00661674] | 10 participants (Actual) | Interventional | 2008-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -0.44 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.68 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.59 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in BDIS (Ondansetron) | Change in BDIS (Placebo) | |
| Prevention of Physical Dependence | -0.6 | 0.2 |
"Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 3.6 | 3.6 |
"Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Physical Dependence | 4.5 | 4.2 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in VAS Score (Ondansetron) | Change in VAS Score (Placebo) | |
| Prevention of Physical Dependence | -2.9 | -2.8 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in RMDI (Ondansetron) | Change in RMDI (Placebo) | |
| Prevention of Physical Dependence | -4.6 | -2.0 |
The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 12.5 | 12.2 |
The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Physical Dependence | 16.4 | 12.0 |
Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS Score (Ondansetron) | Change in POMS Score (Placebo) | |
| Prevention of Opioid Withdrawal | 29.3 | 28.3 |
(Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS (Ondansetron) | Change in POMS (Placebo) | |
| Prevention of Physical Dependence | 36.1 | 29.2 |
The OOWS consists of 13 observable physical symptoms that are assessed over a five-minute observation period and scored as present (score of 1) or absent (score of 0). The total OOWS scores is determined by summing the scores of the 13 items. OOWS scores can range from a low of 0 to a high of 13. A score of 0 would suggest that no objective signs of withdrawal were observed while a score of 13 would suggest that every observable sign of withdrawal was observed. (NCT01006707)
Timeframe: 15 Minutes Following Ondansetron or Placebo Administration
| Intervention | units on a scale (Mean) |
|---|---|
| Ondansetron | 2.7 |
| Placebo | 2.2 |
The OOWS consists of 13 observable physical symptoms that are assessed over a five-minute observation period and scored as present (score of 1) or absent (score of 0). The total OOWS scores is determined by summing the scores of the 13 items. OOWS scores can range from a low of 0 to a high of 13. A score of 0 would suggest that no objective signs of withdrawal were observed while a score of 13 would suggest that every observable sign of withdrawal was observed. (NCT01006707)
Timeframe: 5 Minutes Following Ondansetron or Placebo Administration
| Intervention | units on a scale (Mean) |
|---|---|
| Ondansetron | 1 |
| Placebo | 2 |
The SOWS consists of 16 physical and emotional symptoms that are rated by the participant on a scale from 0 (not at all) to 4 (extremely), to indicate the extent to which the symptom describes how they are feeling at the time. The total SOWS score is determined by summing the scores of the 16 items. Scores range from a low of 0 to a high of 64. A score of 0 would suggest that the individual is experiencing no symptoms of withdrawal while a score of 64 would suggest that the individual is experiencing all 16 symptoms of withdrawal to the fullest extent possible. (NCT01006707)
Timeframe: 20 minutes following Ondansetron or Placebo administration
| Intervention | units on a scale (Mean) |
|---|---|
| Ondansetron | 5.7 |
| Placebo | 8.1 |
Changes are reporting using Spearman's correlation coefficient, using within-subject factors of time (pre-naloxone, post-naloxone) and pre-treatment (placebo, ondansetron). Changes in Objective Opioid Withdrawal Scale (OOWS) and Subjective Opioid Withdrawal Scale (SOWS) with correlation coefficient >0.45 are reported. The OOWS consists of 13 observable physical symptoms assessed over a 5-minute observation period and scored as present (score of 1) or absent (score of 0). The total OOWS scores is determined by summing the scores of the 13 items. OOWS scores can range from 0 to 13; lower scores correspond to fewer symptoms. SOWS consists of 16 physical and emotional symptoms rated by the participant on a scale from 0 (not at all) to 4 (extremely), to indicate the extent to which the symptom describes how they are feeling at the time. The total SOWS score is determined by summing the scores of the 16 items. Scores range from 0 to 64; lower scores correspond to fewer symptoms. (NCT01006707)
Timeframe: 36 minutes
| Intervention | correlation coefficient (Number) | |||||
|---|---|---|---|---|---|---|
| Left inferior frontal gyrus, orbital (OOWS) | Right inferior frontal gyrus, orbital (OOWS) | Right superior frontal gyrus, medial (SOWS) | Right inferior frontal gyrus, orbital (SOWS) | Left superior temporal gyrus (OOWS) | Left caudate head (SOWS) | |
| All Ondansetron | 0.519 | 0.562 | 0.478 | 0.486 | -0.612 | 0.475 |
"The OOWS is a 13-item instrument documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. Maximum score possible = 13, minimum score possible = 0. T=15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~OOWS scores at T=180 is the primary outcome measure of the study compared with baseline OOWS scores at T=-30 (30 minutes prior to study medication administration). Reported time frames are in relation to time past since administration of study medications.~Mean post-Naloxone OOWS scores (+/- SEM) were determined for pretreatment groups" (NCT00661674)
Timeframe: Change from baseline in OOWS score at 180 minutes (15 minutes post naloxone administration)
| Intervention | units on a scale (OOWS Scale) (Mean) |
|---|---|
| Placebo | 3.5 |
| Palonosetron | 1.0 |
| Palonosetron + Hydroxyzine | 0 |
"The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. 15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~The highest score possible (64) would indicate that the individual was experiencing every symptom of opioid withdrawal to the fullest extent possible while the lowest score (0) would indicate that the individual was not experiencing any symptoms of opioid withdrawal.~Mean post-naloxone SOWS scores (+/- SEM) were computed for pretreatment groups: Placebo, palonosetron, and palonosetron with hydroxyzine" (NCT00661674)
Timeframe: Change from baseline in SOWS score at 180 minutes (15 minutes post naloxone administration)
| Intervention | units on a scale (SOWS Scale) (Mean) |
|---|---|
| Placebo | 6.0 |
| Palonosetron | 4.0 |
| Palonosetron + Hydroxyzine | 3.5 |
6 trials available for ondansetron and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Ondansetron does not prevent physical dependence in patients taking opioid medications chronically for pain control.
Topics: Adult; Analgesics, Opioid; Anti-Anxiety Agents; Chronic Pain; Double-Blind Method; Female; Follow-Up | 2018 |
Impact of Ondansetron on Withdrawal Signs, Fentanyl Requirement and Pain Relief in Opioid-addicted Patients under General Anesthesia.
Topics: Adolescent; Adult; Aged; Anesthesia, General; Blood Pressure; Double-Blind Method; Fentanyl; Humans; | 2019 |
Acute opioid withdrawal is associated with increased neural activity in reward-processing centers in healthy men: A functional magnetic resonance imaging study.
Topics: Adult; Brain; Cross-Over Studies; Double-Blind Method; Functional Neuroimaging; Healthy Volunteers; | 2015 |
A pilot study of full-dose ondansetron to treat heavy-drinking men withdrawing from alcohol in Brazil.
Topics: Adolescent; Adult; Alcohol Deterrents; Alcoholism; Brazil; Central Nervous System Depressants; Doubl | 2013 |
Randomised controlled trial of ondansetron in smoking cessation.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Double-Blind Method; Female; Humans; Male; Middle Age | 1996 |
A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation.
Topics: Alprazolam; Anti-Anxiety Agents; Anxiety; Double-Blind Method; Female; Humans; Lorazepam; Male; Midd | 1998 |
33 other studies available for ondansetron and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
The Neurobiology of Opioid Addiction and the Potential for Prevention Strategies.
Topics: Analgesics, Opioid; Humans; Iatrogenic Disease; Neurobiology; Ondansetron; Opioid-Related Disorders; | 2018 |
Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report.
Topics: Adult; Antidiarrheals; Antiemetics; Antipruritics; Buprenorphine; Clonidine; Deprescriptions; Drug S | 2019 |
Case files of the program in medical toxicology at brown university: amantadine withdrawal and the neuroleptic malignant syndrome.
Topics: Amantadine; Antipsychotic Agents; Diagnosis, Differential; Drug Therapy, Combination; Female; Fluid | 2009 |
Acute anti-emetic withdrawal associated with a hemorrhagic cerebellar arteriovenous malformation.
Topics: Aged; Antiemetics; Arteriovenous Fistula; Cerebellum; Flushing; Humans; Intracranial Arteriovenous M | 2010 |
Distinct mechanisms underlying pronociceptive effects of opioids.
Topics: 2-Amino-5-phosphonovalerate; Analgesics, Opioid; Animals; Disease Models, Animal; Dose-Response Rela | 2011 |
Reversal of cocaine withdrawal-induced anxiety by ondansetron, buspirone and propranolol.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Buspirone; Cocaine; Male; Motor Activity; O | 2012 |
Ondansetron given in the acute withdrawal from a repeated cocaine sensitization dosing regimen reverses the expression of sensitization and inhibits self-administration.
Topics: Acute Disease; Animals; Behavior, Animal; Brain; Cocaine; Cocaine-Related Disorders; Disease Models, | 2002 |
Ondansetron, given during the acute cocaine withdrawal, attenuates oral cocaine self-administration.
Topics: Administration, Oral; Animals; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; Male; Onda | 2004 |
Reduction in methamphetamine induced sensitization and reinstatement after combined pergolide plus ondansetron treatment during withdrawal.
Topics: Animals; Drug Therapy, Combination; Male; Methamphetamine; Ondansetron; Pergolide; Rats; Rats, Sprag | 2007 |
Neonatal extrapyramidal movements. Neonatal withdrawal due to maternal citalopram and ondansetron use.
Topics: Adult; Anti-Anxiety Agents; Basal Ganglia Diseases; Citalopram; Female; Humans; Infant, Newborn; Lor | 2008 |
The role of 5-HT in the anxiogenic effects of acute ethanol withdrawal and in the long-lasting cognitive deficits.
Topics: Animals; Anxiety; Buspirone; Cognition Disorders; Ethanol; Exploratory Behavior; Hippocampus; In Vit | 1993 |
Ondansetron and opiate craving. A novel pharmacological approach to addiction.
Topics: Female; Humans; Male; Methadone; Narcotics; Ondansetron; Substance Withdrawal Syndrome; Substance-Re | 1995 |
Conflicting evidence regarding the efficacy of ondansetron in benzodiazepine withdrawal.
Topics: Animals; Anti-Anxiety Agents; Chlordiazepoxide; Conditioning, Psychological; Discrimination Learning | 1993 |
Potentiation of physical dependence on diazepam by ondansetron in rats.
Topics: Animals; Body Weight; Diazepam; Drug Synergism; Male; Ondansetron; Rats; Rats, Inbred F344; Substanc | 1994 |
5-HT3 receptor modulation of behavior during withdrawal from continuous or intermittent cocaine.
Topics: Animals; Behavior, Animal; Cocaine; Dose-Response Relationship, Drug; Infusions, Intravenous; Male; | 1994 |
Voluntary oral morphine self-administration in rats: effect of haloperidol or ondansetron.
Topics: Animals; Behavior, Animal; Defecation; Haloperidol; Injections, Intramuscular; Male; Morphine; Morph | 1994 |
Ultrashort noninvasive opiate detoxification.
Topics: Adult; Heroin Dependence; Humans; Male; Midazolam; Naloxone; Naltrexone; Ondansetron; Substance With | 1993 |
Rat brain monoamine oxidase A and B inhibitory (tribulin) activity during drug withdrawal anxiety.
Topics: Animals; Anxiety; Brain; Brain Chemistry; Cannabis; Ethanol; Isatin; Isoenzymes; Lorazepam; Male; Mo | 1995 |
Blockade of cocaine sensitization and tolerance by the co-administration of ondansetron, a 5-HT3 receptor antagonist, and cocaine.
Topics: Animals; Behavior, Animal; Cocaine; Dose-Response Relationship, Drug; Drug Implants; Drug Tolerance; | 1997 |
Prevention of morphine discontinuation phenomenon in mice by ondansetron, a selective 5-HT3 antagonist.
Topics: Analgesics, Opioid; Animals; Drug Interactions; Drug Tolerance; Female; Male; Mice; Morphine; Morphi | 1996 |
Attenuation of mecamylamine-precipitated nicotine-withdrawal aversion by the 5-HT3 receptor antagonist ondansetron.
Topics: Animals; Conditioning, Psychological; Male; Mecamylamine; Nicotine; Nicotinic Antagonists; Ondansetr | 1997 |
Blockade of the expression of sensitization and tolerance by ondansetron, a 5-HT3 receptor antagonist, administered during withdrawal from intermittent and continuous cocaine.
Topics: Animals; Cocaine; Drug Tolerance; Male; Models, Psychological; Narcotics; Ondansetron; Rats; Rats, S | 1998 |
Effects of ondansetron administration on opioid withdrawal syndrome observed in rats.
Topics: Animals; Behavior, Animal; Body Temperature; Defecation; Male; Morphine; Naloxone; Narcotic Antagoni | 1997 |
Effects of ondansetron administration on opioid withdrawal syndrome observed in rats.
Topics: Animals; Behavior, Animal; Body Temperature; Defecation; Male; Morphine; Naloxone; Narcotic Antagoni | 1997 |
Effects of ondansetron administration on opioid withdrawal syndrome observed in rats.
Topics: Animals; Behavior, Animal; Body Temperature; Defecation; Male; Morphine; Naloxone; Narcotic Antagoni | 1997 |
Effects of ondansetron administration on opioid withdrawal syndrome observed in rats.
Topics: Animals; Behavior, Animal; Body Temperature; Defecation; Male; Morphine; Naloxone; Narcotic Antagoni | 1997 |
Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term results.
Topics: Administration, Oral; Adolescent; Adult; Anesthesia, General; Clonidine; Drug Therapy, Combination; | 1998 |
Treatment of venlafaxine discontinuation symptoms with ondansetron.
Topics: Adult; Cyclohexanols; Depressive Disorder; Female; Humans; Ondansetron; Selective Serotonin Reuptake | 1998 |
Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze.
Topics: Adrenergic alpha-Antagonists; Animals; Anti-Anxiety Agents; Diazepam; Dioxanes; Idazoxan; Imidazoles | 1992 |
Evaluation of anxiolytic action of ondansetron in rats during withdrawal from chronic chlordiazepoxide.
Topics: Animals; Anti-Anxiety Agents; Chlordiazepoxide; Flumazenil; Imidazoles; Learning; Male; Ondansetron; | 1992 |
Effects of the 5-HT3 antagonist ondansetron on benzodiazepine-induced operant behavioural dependence in rats.
Topics: Animals; Chlordiazepoxide; Conditioning, Operant; Female; Ondansetron; Rats; Rats, Wistar; Reinforce | 1992 |
Effects of 5-HT3 receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal.
Topics: Animals; Behavior, Animal; Chlordiazepoxide; Conditioning, Operant; Drug Implants; Imidazoles; Male; | 1991 |
Effects of the 5-HT3 antagonist GR38032F (ondansetron) on benzodiazepine withdrawal in rats.
Topics: Animals; Anti-Anxiety Agents; Body Weight; Chlordiazepoxide; Dose-Response Relationship, Drug; Eatin | 1990 |
Sites of action of ondansetron to inhibit withdrawal from drugs of abuse.
Topics: Amygdala; Animals; Exploratory Behavior; Illicit Drugs; Imidazoles; Injections, Intraventricular; Ma | 1990 |
Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse.
Topics: Animals; Cocaine; Ethanol; Exploratory Behavior; Illicit Drugs; Imidazoles; Male; Mice; Nicotine; On | 1990 |
The effects of ondansetron (GR38032F) in rats and mice treated subchronically with diazepam.
Topics: Animals; Anti-Anxiety Agents; Avoidance Learning; Buspirone; Darkness; Diazepam; Flumazenil; Imidazo | 1989 |